Welcome to our dedicated page for Macrogenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics stock.
MacroGenics, Inc. (Nasdaq: MGNX) is a biopharmaceutical company that publicly describes its focus as discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The MGNX news page on Stock Titan aggregates company-issued updates and third-party coverage so readers can follow how MacroGenics communicates progress across its oncology pipeline, technology platforms and collaborations.
In its press releases, MacroGenics highlights clinical developments for programs such as lorigerlimab, a bispecific PD‑1 × CTLA‑4 DART® molecule, and a portfolio of antibody-drug conjugates including MGC026, MGC028 and MGC030. News items also describe partnered programs like MGD024 with Gilead Sciences, ZYNYZ® (retifanlimab-dlwr) with Incyte and TZIELD® (teplizumab-mzwv) associated with Sanofi, including milestone structures and royalty arrangements disclosed by the company.
MacroGenics regularly issues announcements on quarterly financial results, cash runway expectations, royalty purchase agreements and other financing-related transactions. Additional news covers participation in healthcare and investment conferences, leadership changes such as the appointment of a new President and Chief Executive Officer, and updates on strategic priorities for advancing its antibody-based oncology portfolio and technology platforms.
Investors and observers who follow MGNX news can use this page to review how MacroGenics reports progress in its clinical trials, describes its collaborations and outlines its financial position in official communications. Bookmarking the news feed provides a centralized view of press releases and related information that the company files or references in its SEC disclosures.
MacroGenics, Inc. (Nasdaq: MGNX) will release its third-quarter 2021 financial results after the market closes on November 2, 2021. A conference call to discuss these results and recent corporate developments will be held on the same date at 4:30 pm ET. Investors can join the call by dialing the appropriate access numbers five minutes prior to the start. The presentation will also be available via a listen-only webcast on the company's Investor Relations website, with a recorded replay accessible for 30 days post-call.
MacroGenics announced promising interim results from Part 1 of the Phase 2/3 MAHOGANY clinical trial for margetuximab, targeting HER2+ gastric cancer. Out of 40 evaluated patients, 21 achieved confirmed responses, exceeding the trial's futility boundaries. The combination therapy demonstrated a 78% tumor shrinkage rate and a median response duration of 10.3 months. The treatment was well tolerated, with only 19% experiencing Grade 3 adverse events. These findings support advancing to Part 2 of the trial, with potential implications for first-line treatment options.
MacroGenics (NASDAQ: MGNX) announced preliminary safety and anti-tumor results from the Phase 1 trial of MGC018, an investigational antibody-drug conjugate. In metastatic castration-resistant prostate cancer (mCRPC), 54% of patients showed ≥ 50% PSA reduction, while 63% of evaluable patients displayed anti-tumor activity. In non-small cell lung cancer (NSCLC), 81% of evaluable patients had anti-tumor activity. The treatment demonstrated a manageable safety profile with only 7% discontinuation due to treatment-related adverse events. Further updates on other cohorts are anticipated.
On September 12, 2021, MacroGenics (Nasdaq: MGNX) announced multiple poster presentations for its investigational product candidates at the ESMO Virtual Conference scheduled for September 16-21, 2021. Key presentations include preliminary results for MGC018, an antibody-drug conjugate targeting advanced solid tumors, and data from the MAHOGANY trial on margetuximab in HER2+, PD-L1+ gastroesophageal adenocarcinoma. The posters will be accessible on the ESMO website and MacroGenics' investor relations page.
MacroGenics announced the final overall survival (OS) results of the SOPHIA Phase 3 study for MARGENZA (margetuximab-cmkb) in HER2-positive metastatic breast cancer. The study showed no statistically significant OS advantage for MARGENZA plus chemotherapy (21.6 months) compared to trastuzumab plus chemotherapy (21.9 months; HR=0.95, P=0.62). However, a subgroup analysis indicated improved OS in patients with the CD16A 158F allele. Safety profiles were consistent with prior reports. Further studies are planned to explore MARGENZA's effects based on CD16A variants.
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company, announced its participation in several investor conferences in September 2021. The events include Citi’s 16th Annual BioPharma Virtual Conference on September 9, featuring a panel discussion on oncology therapies. Additionally, MacroGenics will engage in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15 and another at the 2021 Cantor Virtual Global Healthcare Conference on September 30.
Webcasts of these presentations will be available on the company's investor relations website.
MacroGenics, Inc. (Nasdaq: MGNX) announced its participation in two key conferences in August 2021. The first event is the BTIG Virtual Biotechnology Conference on August 10, where management will engage in a fireside chat at 9:30 am ET and conduct one-on-one meetings. The second is the 12th Annual Wedbush PacGrow Healthcare Conference on August 11, featuring CEO Scott Koenig in a panel discussion titled ADCs – Take Me to Your Tumor at 2:20 pm ET, along with one-on-one meetings. Webcast access for these events is available on their website.
MacroGenics, Inc. (NASDAQ: MGNX) reported its Q2 2021 financial results, highlighting a revenue increase to $30.8 million, up from $20.3 million in Q2 2020, driven by collaborations and MARGENZA sales. The company is progressing with its clinical pipeline, including upcoming data presentations at ESMO. Key financials include a net loss of $39.9 million and total cash and equivalents of $297.3 million as of June 30, 2021. Guidance indicates funding through 2023, contingent on program advancements.
MacroGenics, a biopharmaceutical company focused on monoclonal antibody therapeutics for cancer, will release its financial results for Q2 2021 on July 29, 2021, after market close. A conference call to discuss these results and corporate progress will be held the same day at 4:30 PM ET. Interested parties can access the call by dialing (877) 303-6253 for domestic calls or (973) 409-9610 for international calls. The call will also be available via a webcast on the company's investor relations page.
MacroGenics (NASDAQ: MGNX) has announced a significant collaboration with Zai Lab, granting exclusive rights to develop up to four bispecific molecules targeting immuno-oncology. The deal includes an upfront payment of $25 million and a $30 million equity investment in MacroGenics at $31.30 per share. The collaboration allows both companies to leverage their intellectual properties, with Zai receiving rights in Greater China, Japan, and Korea, and MacroGenics retaining rights in other territories. Potential milestone payments could total $1.4 billion, along with royalties from net sales.